Skip to main content

Table 2 Change from baseline (expressed as a ratio) in 24-h weighted mean SC at week 6

From: A randomized, double-blind, placebo-controlled, parallel-group study of once-daily inhaled fluticasone furoate on the hypothalamic–pituitary–adrenocortical axis of children with asthma

VariablesPlacebo groupFF 50 QD group
SC population
 N5153
 n5052
 LS geometric mean (nmol/L)173.25160.65
 LS ratio to baseline1.050.97
 FF 50 QD/placebo ratio0.93
 95% CI0.8096, 1.0620
ITT population
 N5556
 n5153
 LS geometric mean (nmol/L)174.08159.98
 LS ratio to baseline1.060.97
 FF 50 QD/placebo ratio0.92
 95% CI0.8040, 1.0505
  1. CI confidence interval, FF 50 QD fluticasone furoate 50 µg once daily, h hours, ITT intent-to-treat, LS least squares, SC serum cortisol, N number of subjects in population, n number of subjects with value at the visit